A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Hofgaard, Peter O ^a   Jodal, Henriette C ^a   Bommert, Kurt ^b   Huard, Bertrand ^c   Caers, Jo ^d   Carlsen, Harald ^e   Schwarzer, Rolf ^f   Schünemann, Nicole ^f   Jundt, Franziska ^f,g   Lindeberg, Mona M ^a   Bogen, Bjarne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e UNIVERSITY OF OSLO   (Norway)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIREFLY LUCIFERASE; PARAPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE ATROPHY; BONE MARROW CELL; CARCINOGENICITY; CELLULAR DISTRIBUTION; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL MOUSE; FEMUR; GENETIC TRANSFECTION; IMAGE ANALYSIS; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; PARAPLEGIA; PROTEIN BLOOD LEVEL; SIGNAL DETECTION; SPATIOTEMPORAL ANALYSIS; SPINAL CORD COMPRESSION; SPLEEN; TIBIA; TROPISM;

ANIMALS; BONE MARROW; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENES, REPORTER; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; MULTIPLE MYELOMA; OSTEOLYSIS; TRANSFECTION;

MUS;

EID: 84871436882     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051892     Document Type: Article

References (52)

1. Anderson KC, (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 35: 155-162.
2. Feo-Zuppardi FJ, Taylor CW, Iwato K, Lopez MH, Grogan TM, et al. (1992) Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 80: 2843-2850.
3. Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, et al. (1993) Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 53: 1392-1396.
4. Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, et al. (1997) New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood 90: 2437-2444.
5. Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, et al. (1999) Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14: 256-263.
6. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, et al. (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95: 1056-1065.
7. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, et al. (2004) Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 313: 258-262.
8. Mitsiades CS, Anderson KC, Carrasco DR (2007) Mouse models of human myeloma. Hematol Oncol Clin North Am 21: 1051-69, viii.
9. Yaccoby S, Barlogie B, Epstein J, (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92: 2908-2913.
10. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, et al. (2011) A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25: 707-711.
11. Radl J, De Glopper ED, Schuit HR, Zurcher C, (1979) Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122: 609-613.
12. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM, (1988) Animal model of human disease. Multiple myeloma. Am J Pathol 132: 593-597.
13. Radl J, (1999) Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris) 47: 109-114.
14. Vanderkerken K, Asosingh K, Croucher P, Van CB, (2003) Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 194: 196-206.
15. Vanderkerken K, De RH, Goes E, Van MS, Radl J, et al. (1997) Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 76: 451-460.
16. Vanderkerken K, Goes E, De RH, Radl J, Van CB, (1996) Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. Br J Cancer 73: 1463-1465.
17. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG, et al. (1992) A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 66: 1088-1093.
18. Garrett IR, Dallas S, Radl J, Mundy GR, (1997) A murine model of human myeloma bone disease. Bone 20: 515-520.
19. Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, et al. (2004) Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104: 2149-2154.
20. Oyajobi BO, Munoz S, Kakonen R, Williams PJ, Gupta A, et al. (2007) Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 6: 1701-1708.
21. Cheung WC, Kim JS, Linden M, Peng L, Van NB, et al. (2004) Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 113: 1763-1773.
22. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, et al. (2008) AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13: 167-180.
23. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, et al. (2007) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11: 349-360.
24. Potter M, (1972) Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev 52: 631-719.
25. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN, (1972) Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 69: 1540-1544.
26. Lauritzsen GF, Weiss S, Dembic Z, Bogen B, (1994) Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 91: 5700-5704.
27. Dembic Z, Schenck K, Bogen B, (2000) Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A 97: 2697-2702.
28. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, et al. (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity 22: 371-383.
29. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B, (2009) Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res 69: 5901-5907.
30. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, et al. (2011) Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2: 240.
31. Potter M, Fahey JL, Pilgrim HI, (1957) Abnormal serum protein and bone destruction in transmissible mouse plasma cell neoplasm (multiple myeloma). Proc Soc Exp Biol Med 94: 327-333.
32. Kobayashi H, Potter M, Dunn TB, (1962) Bone lesions produced by transplanted plasma-cell tumors in BALB/c mice. J Natl Cancer Inst 28: 649-677.
33. Dellacasagrande J, Schreurs OJ, Hofgaard PO, Omholt H, Steinsvoll S, et al. (2003) Liver metastasis of cancer facilitated by chemokine receptor CCR6. Scand J Immunol 57: 534-544.
34. Lauritzsen GF, Bogen B, (1993) The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 148: 177-188.
35. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
36. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, et al. (1999) Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A 96: 12044-12049.
37. Vanderkerken K, De GC, Asosingh K, Arteta B, De VM, et al. (2000) Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer 82: 953-959.
38. Rohrer JW, Vasa K, Lynch RG, (1977) Myeloma cell immunoglobulin expression during in vivo growth in diffusion chambers: evidence for repetitive cycles of differentiation. J Immunol 119: 861-866.
39. Daley MJ, Bridges SH, Lynch RG, (1978) Plasmacytoma spleen colonization: a sensitive, quantitative in vivo assay for idiotype-specific immune suppression of MOPC-315. J Immunol Methods 24: 47-56.
40. Potter M, (2003) Neoplastic development in plasma cells. Immunol Rev 194: 177-195.
41. O'Connor BP, Gleeson MW, Noelle RJ, Erickson LD, (2003) The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev 194: 61-76.
42. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC, (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104: 607-618.
43. Mellstedt H, Hammarstrom S, Holm G, (1974) Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol 17: 371-384.
44. Bakkus MH, Van Riet I, Van Camp B, Thielemans K, (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 87: 68-74.
45. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, et al. (1998) A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92: 2844-2855.
46. Wiltshaw E, (1976) The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore) 55: 217-238.
47. Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, et al. (2004) Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis 33: 111-119.
48. Eisen HN, Simms ES, Potter M, (1968) Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315. Biochemistry 7: 4126-4134.
49. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, et al. (1995) Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 25: 3079-3086.
50. Salamon M, Hanke R, Krüger P, Uhlmann N, Voland V (2008) Realization of a computed tomography setup to achieve resolutions below 1 micrometer. Nuclear Instruments and Methods in Physics Research A 591.
51. Nachtrab F, Salamon M, Burtzlaff S, Porsch F, Johannson W, et al. (2008) Progress in sub-micrometer resolution computed tomography. Nuclear Science Symposium Conference Record, 2008 NSS '08 IEEE 532-535.
52. Doube M, Klosowski MM, Arganda-Carreras I, Cordelieres FP, Dougherty RP, et al. (2010) BoneJ: Free and extensible bone image analysis in ImageJ. Bone 47: 1076-1079.